LXRX Lexicon Pharmaceuticals Inc

$LXRX 🔥🔥🔥 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a Overweight rating, PT $8.00.

$LXRX Horror just horror, i thought we won't go under 2$ again but this ticker always likes to disappoint.

$LXRX I still think that we are at the bottom here. I sure wish I had some dry powder, but unfortunately, I don’t! 😆 Doc C. 🤓

$LXRX I couldn't tell you when to add any better than when we see humble-bob and Woo_S both coming out to trash the stock. Now it is confirmed, and I added a few more shares of LXRX today using my monthly dividends from YYY. Thank you both so that I don't have to do my DD or read the charts.

$LXRX it’s been 3 months downwards. I feel frustrated…. Any of you guys feel the same way?

$LXRX I’m ready for that PR of Zynquista NDA submission along with the DKA rates the data shows. Shorts will cover and squeeze this.

$LXRX Who wakes up and says - an investment banker came out yesterday and said this stock will be $8 in a year and there are 4 or so catalysts occurring in next 6 months, but you know what, I think I will sell my stock for $1.82. I just dont understand.

$LXRX which will happen first in 2027? Disclosure of aliens on earth, or Lexicon hitting $4?

$LXRX get ready for the 2027 blitz! Zynquista decision, HCM results, Novo milestone payout, pilavapadin partnering. All before mid year.

$LXRX Look at the chart its been a while since we had a pull back, part of the process!!! Every time it shoots up nice after!!! Praying for the same again. Only time will tell , i loaded up more today!! Scared money don’t make money!!!!

$LXRX Zynquista should send this flying if the DKA rates are similar to standard of care, FDA won't have ground to refuse it anymore.

$LXRX At this point all we can say is that Lexi has the potential for success, while it has not had any meaningful and sustainable revenue owing its 26-year existence as a public company, and its controlling shareholder seldom defends its SP. As a result, it has become one of the ideal targets for manipulation by hedge funds & MMs. Until Lexi can bring in sustainable revenue with sizable profits, it will remain as an ATM machine for Tutes and MMs. How far is it from decommissioning this generous ATM machine? I think we're just 6 to 8 months away, which is the time span for Zynquista/T1D's NDA resubmission and approval. Afterwards, Inpefa/HCM will add to the mix followed by Pilavapadin/DPNP and LX9851. The bad news is that escalating volatilities will be here to stay, where fundamental and technical analyses mean very little foretelling SP movements. The good news is that 6 months is not very long, when other catalyts such as LX9851 P1 readout & P2 start will hit news stand as well.

$LXRX Will be hilarious when submittal is anounced. And short coverage takes us to 5 bucks+ hah hah hah ...

$LXRX Added more after a successful day trade on another ticker. Loaded with Lexi across three different accounts. Patience will pay off! 💪

$LXRX My SP prediction: By EOY/26 after the Zynquista/T1D resubmission - $2.50 to $3.50 By EOQ1/27 after Inpefa/HCM readout - $4.00 to $5.00 By EOY/27 after FDA approval of Inpefa for HCM - $6.00 to $8.00 In the meantime, Novo should have advanced LX9851 to P3 trials with approval in 2028 with $1B milestone payments to LXRX - SP > $10.0 The Pilavapadin clinical advancement with a partner or not should add $5.00 to the SP. GLTA and Cheers!

$LXRX Long and bullish. Sitting in the doldrums waiting for news that should come in the next couple of months. Wouldn't be completely surprised to see us touch the 1.50s before bouncing back. At this point I'm along for the ride and enjoying the $AMD climb in the meantime. GLTA!

$LXRX Been trading bio stocks for years and have learned that when share price drops like today without no news and no increase in volume, or any reason you should never panic. Sit tight, same old mm shenanigans. I am down to 2 bio stocks...lxrx and cgtx. When I get my target sell I am out of the stock market for good with the only exception of blue chip high dividend paying securities. Way too much manipulation and corruption. On Monday close at 2.04, Tues open at 2.17 then down to 1.91 today? Comoany management doesnt help much either. Investor insecurity is also baked in especially when CEO says things like partnership talks moving along, good news coming soon, fda approval just around the corner and nothing happens. Some people have been chasing lxrx for years. Tock tock..tick tock....2027 or bust.

$LXRX given Novo’s relationship with Steno in Denmark, I assume they may be helping LXRX with the resubmission, and thus, have perspective on how derisked this opportunity is as an adjunct to insulin in T1D. Very easy plug and play, with a lot of optionality and can retire potential liabilities/ milestone payments with obesity

🚨$LXRX $NVO ATTENTION SHOPPERS, NVO GOING PLACES...🚨 Novo secured exclusive worldwide rights to LX9851 for ALL indications 🌎🔥 💊 Oral ACSL5 inhibitor 🎯 Obesity + metabolic disorders 🧬 Potential GLP-1 combo 💰 Up to $1B in milestones + royalties More pipeline optionality. More shots on goal. 📈🐂 $NVO $LXRX looking interesting here 👀 SEC fillings for those that need proof: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000029/exh101novonordisk-exclus.htm ...

$LXRX I could not disagree more. If the HCM readout is above average/great and the sp remains around $3/share, I am out and most people are out as well. LXRX has until end Q1/end Q2 at the most to make a significant move or I believe most people are out. Time for patience is completely over after that time period.